Puma Biotechnology (PBYI) Stock Analysis
NASDAQHealthcareBiotechnology
What Puma Biotechnology does
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
Key metrics
ETFs linked to PBYI
Broad-market and Healthcare sector ETFs an investor holding Puma Biotechnology is often also exposed to. Open an ETF page to see its actual top holdings.
PortView Portfolio Insights
PortView analyzes how PBYI fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze PBYI in PortView →Similar companies
Frequently asked questions
- What is the ticker symbol for Puma Biotechnology?
- Puma Biotechnology trades under the ticker PBYI on NASDAQ.
- Which exchange is PBYI listed on?
- PBYI is listed on NASDAQ.
- What sector does Puma Biotechnology operate in?
- Puma Biotechnology is classified in the Healthcare sector (Biotechnology industry).
- How can PortView help analyze PBYI in a portfolio?
- PortView shows PBYI's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.